Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19
Status:
Completed
Trial end date:
2021-09-07
Target enrollment:
Participant gender:
Summary
This is Phase 2 multi-center controlled randomized study to assess the efficacy and safety of
MIR 19® via 14 days of treatment of participants with symptomatic moderate COVID-19.
The purpose of this study is to evaluate the efficacy, safety and daily dose of MIR 19 ® for
the treatment of the hospitalized patients with infection caused by SARS-CoV-2 (COVID-19) who
did not require treatment in the intensive care unit.
Based on preclinical data studying antiviral effect of MIR 19® in vitro and in vivo (Khaitov
M.R. et all 2021), the investigators hypothesized that SARS-CoV-2 inhibition with MIR 19®
could potentially reduce pulmonary inflammation, thereby improving COVID-19 patient outcomes.
Phase:
Phase 2
Details
Lead Sponsor:
National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
Collaborator:
St. Petersburg Research Institute of Vaccines and Sera